Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics.

Pulley JM, Shirey-Rice JK, Lavieri RR, Jerome RN, Zaleski NM, Aronoff DM, Bastarache L, Niu X, Holroyd KJ, Roden DM, Skaar EP, Niswender CM, Marnett LJ, Lindsley CW, Ekstrom LB, Bentley AR, Bernard GR, Hong CC, Denny JC
Assay Drug Dev Technol. 2017 15 (3): 113-119

PMID: 28379727 · PMCID: PMC5399743 · DOI:10.1089/adt.2016.772

The potential impact of using human genetic data linked to longitudinal electronic medical records on drug development is extraordinary; however, the practical application of these data necessitates some organizational innovations. Vanderbilt has created resources such as an easily queried database of >2.6 million de-identified electronic health records linked to BioVU, which is a DNA biobank with more than 230,000 unique samples. To ensure these data are used to maximally benefit and accelerate both de novo drug discovery and drug repurposing efforts, we created the Accelerating Drug Development and Repurposing Incubator, a multidisciplinary think tank of experts in various therapeutic areas within both basic and clinical science as well as experts in legal, business, and other operational domains. The Incubator supports a diverse pipeline of drug indication finding projects, leveraging the natural experiment of human genetics.

MeSH Terms (8)

Databases, Genetic Drug Design Drug Repositioning Genetic Predisposition to Disease Genome, Human Humans Pharmacogenomic Testing Precision Medicine

Connections (6)

This publication is referenced by other Labnodes entities:

Links